Simultaneous 68Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor

Thomas A. Hope, Miguel Hernandez Pampaloni, Eric Nakakura, Henry VanBrocklin, James Slater, Salma Jivan, Carina Mari Aparici, Judy Yee, Emily Bergsland

Research output: Contribution to journalArticle

47 Scopus citations

Abstract

Objective: To evaluate a simultaneous PET/MRI approach to imaging patients with neuroendocrine tumor using a combination of 68Ga-DOTA-TOC as a PET contrast agent and gadoxetate disodium as a hepatobiliary MRI contrast agent. Materials and methods: Ten patients with neuroendocrine tumor with known or suspected hepatic disease were imaged using a 68Ga-DOTA-TOC PET/CT immediately followed by a 3.0T time-of-flight PET/MRI, using a combined whole body and liver specific imaging. The presence of lesions and DOTA-TOC avidity were assessed on CT, PET from PET/CT, diffusion weighted imaging, hepatobiliary phase imaging (HBP), and PET from PET/MRI. Maximum standardized uptake values (SUVmax) in hepatic lesions and nodal metastases were compared between PET/CT and PET/MRI, as were detection rates using each imaging approach. Results: A total of 101 hepatic lesions were identified, 47 of which were DOTA-TOC avid and able to be individually measured on both PET/CT and PET/MRI. HBP imaging had a higher sensitivity for detection of hepatic lesions compared to CT or PET (99% vs. 46% and 64%, respectively; p values <0.001). There was a strong correlation between SUVmax of liver lesions obtained with PET/CT compared to PET/MR imaging (Pearson’s correlation = 0.91). For nodal disease, CT had a higher sensitivity compared to whole body MRI (p = 0.015), although PET acquired from PET/MRI detected slightly more lesions compared to PET from PET/CT. Conclusions: A simultaneous PET/MRI using both 68Ga-DOTA-TOC and gadoxetate disodium was successful in whole body staging of patients with neuroendocrine tumor. HBP imaging had an increased detection rate for hepatic metastases.

Original languageEnglish (US)
Pages (from-to)1432-1440
Number of pages9
JournalAbdominal Imaging
Volume40
Issue number6
DOIs
StatePublished - Aug 12 2015
Externally publishedYes

Keywords

  • Ga-68 DOTA-TOC
  • Hepatobiliary agents
  • Neuroendocrine tumor
  • PET/MRI

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging
  • Gastroenterology
  • Urology

Fingerprint Dive into the research topics of 'Simultaneous <sup>68</sup>Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor'. Together they form a unique fingerprint.

  • Cite this

    Hope, T. A., Pampaloni, M. H., Nakakura, E., VanBrocklin, H., Slater, J., Jivan, S., Aparici, C. M., Yee, J., & Bergsland, E. (2015). Simultaneous 68Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdominal Imaging, 40(6), 1432-1440. https://doi.org/10.1007/s00261-015-0409-9